Ordinary Rebalance | Solactive Global Vaccines and Infectious Diseases Index | Effective Date 15th February 2024
In the ordinary rebalance, the following composition will be implemented effective open 15.02.2024:
| 3SBIO INC |
| ABBOTT LABORATORIES |
| ABBVIE INC |
| ADMA BIOLOGICS INC |
| ASTRAZENECA PLC |
| BAVARIAN NORDIC A/S |
| BIONTECH SE |
| BRISTOL-MYERS SQUIBB CO |
| CELLDEX THERAPEUTICS INC |
| DENKA CO LTD |
| DYNAVAX TECHNOLOGIES CORP |
| ELI LILLY & CO |
| GENMAB A/S |
| GILEAD SCIENCES INC |
| GSK PLC |
| IMMUNITYBIO INC |
| JOHNSON & JOHNSON |
| LABORATORY CRP OF AMER HLDGS |
| MARAVAI LIFESCIENCES HOLDINGS INC |
| MERCK & CO. INC. |
| MODERNA INC |
| PFIZER INC |
| REGENERON PHARMACEUTICALS |
| SANOFI SA |
| SHIONOGI & CO LTD ORD |
| SK BIOSCIENCE ORD |
| TG THERAPEUTICS INC |
| VAXCYTE INC |
| VIR BIOTECHNOLOGY INC |
| WUXI BIOLOGICS CAYMAN INC |